It is in a specialty cardiology field - in a growing market.
Should continue to increase in price with increase in earnings.
The products are used in most major cardiac centers.
Also a possible takeover candidate.
I expect the stock to reach 10 dollars within 2 years
In the next 6-12 months..this stock will be over 150.
I expect another 2:1 split later this year.
Once TAVR is approved for average risk individuals - the procedure will become the standard
for Aortic valve replacement.